Abstract session: Hepatitis B and D - Drug development

 Viral hepatitis
 Viral hepatitis

Channel 5
Abstract session
28 August 2020 11:00 - 12:30


Title Time (CET)

Add to Calendar

AS067 Hepatitis B virus (HBV) surface antigen (HBsAg) inhibition with ISIS 505358 in chronic hepatitis B (CHB) patients on stable nucleos(t)ide analogue (NA) regimen and in NA-naive CHB patients: phase 2a, randomised, double-blind, placebo-controlled study
28 August 2020 11:00 - 11:15
AS068 Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients
28 August 2020 11:15 - 11:30
AS069 RO7062931 anti-sense oligonucleotide phase 1 study demonstrates target engagement in patients with chronic hepatitis B on established nucleos(t)ide therapy
28 August 2020 11:30 - 11:45
AS070 Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection
28 August 2020 11:45 - 12:00
AS071 Efficacy and safety of 24 weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B: a phase 2 study
28 August 2020 12:00 - 12:15
AS072 48 weeks of high dose (10mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV coinfection
28 August 2020 12:15 - 12:30